About: covid:PMC7289070

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7289070 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Labopin, Myriam Mohty, Mohamad Baron, Frédéric Sanz, Jaime Bazarbachi, Ali Brissot, Eolia Ciceri, Fabio Gilleece, Maria Lanza, Francesco Nagler, Arnon Ruggeri, Annalisa Savani, Bipin Bug, Gesine Esteve, Jordi Giebel, Sebastian Gorin, Norbert-Claude Peric, Zinaida Schmid, Christoph Shouval, Roni Spyridonidis, Alexandros Versluis, Jurjen
is schema:about of	named entity 'guidelines' named entity 'patients' named entity 'acute leukemia' named entity 'acute leukemia' named entity 'acute leukemia' named entity 'telephone' named entity 'anthracycline' named entity 'minimal residual disease' named entity 'clinical research' named entity 'outpatient visits' named entity 'Molecular targeted therapy' named entity 'COVID' named entity 'blinatumomab' named entity 'COVID-19 outbreak' named entity 'acute lymphoblastic leukemia' named entity 'hygiene measures' named entity 'cytarabine' named entity 'infection' named entity 'all-trans-retinoic acid' named entity 'follow-up' named entity 'fungal infections' named entity 'MRD' named entity 'clinical trials' named entity 'venetoclax' named entity 'APL' named entity 'promyelocyte' named entity 'APL' named entity 'myelosuppression' named entity 'COVID' named entity 'tyrosine kinase' named entity 'venetoclax' named entity 'MRD' named entity 'cytogenetic' named entity 'e-health' named entity 'acute lymphoblastic leukemia' named entity 'outpatient' named entity 'COVID-19' named entity 'differentiation syndrome' named entity 'G-CSF' named entity 'AML' named entity 'ATRA' named entity 'thoracic' named entity 'COVID-19 outbreak' named entity 'venetoclax' named entity 'complete remission' named entity 'infection' named entity 'AML' named entity 'COVID' named entity 'social distancing' named entity 'clinical trial' named entity 'white blood cells' named entity 'neutropenia' named entity 'G-CSF' named entity 'COVID' named entity 'acute lymphoblastic leukemia' named entity 'ICU' named entity 'neutropenia' named entity 'acute lymphoblastic leukemia' named entity 'hospital pharmacies' named entity 'acute myeloid leukemia' named entity 'intensive therapy' named entity 'clinical research' named entity 'comorbidities' named entity 'hypomethylating agents' named entity 'stem cell' named entity 'COVID' named entity 'leukemia' named entity 'infection' named entity 'hydroxycarbamide' named entity 'APL' named entity 'sorafenib' named entity 'clinical trials' named entity 'glucocorticoids' named entity 'medical institution' named entity 'AML' named entity 'hematological' named entity 'gilteritinib' named entity 'computerized tomography' named entity 'blood tests'

Attributes

Values

Creator

Labopin, Myriam
Mohty, Mohamad
Baron, Frédéric
Sanz, Jaime
Bazarbachi, Ali
Brissot, Eolia
Ciceri, Fabio
Gilleece, Maria
Lanza, Francesco
Nagler, Arnon
Ruggeri, Annalisa
Savani, Bipin
Bug, Gesine
Esteve, Jordi
Giebel, Sebastian
Gorin, Norbert-Claude
Peric, Zinaida
Schmid, Christoph
Shouval, Roni
Spyridonidis, Alexandros
Versluis, Jurjen

is schema:about of

named entity 'guidelines'
named entity 'patients'
named entity 'acute leukemia'
named entity 'acute leukemia'
named entity 'acute leukemia'
named entity 'telephone'
named entity 'anthracycline'
named entity 'minimal residual disease'
named entity 'clinical research'
named entity 'outpatient visits'
named entity 'Molecular targeted therapy'
named entity 'COVID'
named entity 'blinatumomab'
named entity 'COVID-19 outbreak'
named entity 'acute lymphoblastic leukemia'
named entity 'hygiene measures'
named entity 'cytarabine'
named entity 'infection'
named entity 'all-trans-retinoic acid'
named entity 'follow-up'
named entity 'fungal infections'
named entity 'MRD'
named entity 'clinical trials'
named entity 'venetoclax'
named entity 'APL'
named entity 'promyelocyte'
named entity 'APL'
named entity 'myelosuppression'
named entity 'COVID'
named entity 'tyrosine kinase'
named entity 'venetoclax'
named entity 'MRD'
named entity 'cytogenetic'
named entity 'e-health'
named entity 'acute lymphoblastic leukemia'
named entity 'outpatient'
named entity 'COVID-19'
named entity 'differentiation syndrome'
named entity 'G-CSF'
named entity 'AML'
named entity 'ATRA'
named entity 'thoracic'
named entity 'COVID-19 outbreak'
named entity 'venetoclax'
named entity 'complete remission'
named entity 'infection'
named entity 'AML'
named entity 'COVID'
named entity 'social distancing'
named entity 'clinical trial'
named entity 'white blood cells'
named entity 'neutropenia'
named entity 'G-CSF'
named entity 'COVID'
named entity 'acute lymphoblastic leukemia'
named entity 'ICU'
named entity 'neutropenia'
named entity 'acute lymphoblastic leukemia'
named entity 'hospital pharmacies'
named entity 'acute myeloid leukemia'
named entity 'intensive therapy'
named entity 'clinical research'
named entity 'comorbidities'
named entity 'hypomethylating agents'
named entity 'stem cell'
named entity 'COVID'
named entity 'leukemia'
named entity 'infection'
named entity 'hydroxycarbamide'
named entity 'APL'
named entity 'sorafenib'
named entity 'clinical trials'
named entity 'glucocorticoids'
named entity 'medical institution'
named entity 'AML'
named entity 'hematological'
named entity 'gilteritinib'
named entity 'computerized tomography'
named entity 'blood tests'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software